2 years ago

MultiOmic Health Raises $6.2M to Advance AI-Powered Drug Discovery

  • MultiOmic Health, a London-based AI-enabled drug discovery company, has secured $6.2 million in funding led by Hoxton Ventures, with participation from Ada Ventures, MMC Ventures and Verve Ventures

  • The funding will be used to demonstrate proof-of-concept for its MOHSAIC platform in diabetic kidney disease

  • MultiOmic Health focuses on metabolic syndrome-related diseases and partners with healthcare providers to source and analyze de-identified patient data and bio-samples

  • Its MOHSAIC platform combines integrated multi-omics analysis and computational systems biology modelling with targeted wet laboratory experiments to originate novel precision therapeutic concepts.

      • ProblemHealthcare

      "MultiOmic Health is addressing the need for more effective and personalized treatments for metabolic syndrome-related diseases, such as diabetic kidney disease."

      Solution

      "The company uses its MOHSAIC platform to integrate multi-omics analysis, computational systems biology modeling, and targeted wet laboratory experiments to develop novel precision therapeutic concepts."

      Covered on